Advances in Systemic Cancer Therapy Alex A. Adjei
|
|
- Mitchell Ward
- 6 years ago
- Views:
Transcription
1 Advances in Systemic Cancer Therapy Alex A. Adjei ESMO Summit Africa February 13, 2017 Cape Town, RSA 2016 MFMER slide-1
2 2016 MFMER slide-2
3 Cancer Cells Adapt to Stress 2016 MFMER slide-3
4 Strategies for Targeting Hallmarks of Cancer 2016 MFMER slide-4
5 Novel Therapeutics Targets - multiple Methods of Inhibiting Targets limited Chemical therapy Small molecule inhibitors Monoclonal Antibodies Chimeric Antibodies Antibody Drug Conjugates Vaccines Adoptive T cell transfer Chimeric Antigen Receptor T-cells RNAi Gene Therapy Viral Therapies Clustered regularly interspaced short palindromic repeats (CRISPR) 2016 MFMER slide-5
6 Targeted Therapeutics 6 ❶ Agents that Target Cell Surface Receptors Endothelial Cell ❺ Anti-angiogenic Agents ❷ Agents that Target Intracellular Signal Transduction Pathways ucleus ❹ Agents that Target Epigenetics ❸ Agents that Target Protein Dynamics Tumor Cell ❻ Agents that Affect Tumor Immunity Immune Cell 2016 MFMER slide-6
7 A typical receptor tyrosine kinase inhibitor of VEGFR-2 VEGF Cell membrane X VEGFR-2 (KDR/Flt-1) Cediranib inhibits RTK activity N O O O N N F N Adapter molecules Endothelial cell X Signal transduction Proliferation and migration Vascular permeability 2016 MFMER slide-7
8 Receptor Tyrosine Kinases 2016 MFMER slide-8
9 Kinase Inhibition by Competing with ATP Binding Domain Goldman JM, Melo JV. N Engl J Med : MFMER slide-9
10 Cancer Targets and their Inhibitors 2016 MFMER slide-10
11 Inhibiting Cyclin-Dependent Kinases 2016 MFMER slide-11
12 Single cyclins Multiple cyclins Cyclin-dependent kinases Yeasts Worms Flies Humans Cdc2/28 Pho85 cdk-1 cdk-2 cdk-4 cdk-5 Cdk1 Cdk2 Cdk4 Cdk5 CDK1 CDK2 CDK3 CDK4 CDK6 CDK5 Ctk1 Kin28 Sgv1/Bur1 Srb10/Ssn3 cdk-11 BO285 CCRK cdk-7 cdk-9 cdk-8 Cdk11 Cdk10 CG7597 Ccrk Cdk7 Cdk9 Cdk8 CDK11 CDK10 CDK13 CDK12 CCRK CDK7 CDK9 CDK8 Malumbres & Barbacid. Nat. Rev. Cancer, 2009 Malumbres et al. Nat Cell Biol, MFMER slide-12
13 Cell Cycle Progression Regulated by GO and STOP SIGNALS growth factors Ras, Raf, Myc, Fos, Jun p18 p19 cdk 4 & 6 PCNA p16 p15 p27 Radiation DNA Damage Chemicals p21 p53 Cyclin H cdk7 p21 P M p27 Rb E2F Cyclin B cdk1 G2 E2F P P Cyclins D Rb P Cyclin Cyclin A A cdk1 cdk1 G1 p107 E2F Cyclin E cdk2 Cyclin A cdk2 p107 E2F S Cyclin Hcdk7 p53 p27 p21 JNCI 92: 376, MFMER slide-13
14 Rationale for Developing a CDK4/6 Inhibitor G0 Growth factors Mitogens CDK4/6 Cyclin D LY p16 Potential Patient Selection (Rb, p16, and cyclin D) M G1 E2F Rb1 DP P Rb1 P P E2F DP G2 Transcription S Cyclin E G1 progression DNA replication P P P Rb1 P P P P P CDK2 Cyclin E Mechanism of Action: Inhibition of CDK4/6 prevents phosphorylation of Rb protein and thereby induces strong G1 arrest in cancer cells Transcription p27 Company Confidential Copyright 2013 Eli Lilly and Company MFMER slide-14
15 Alterations in the CDK4/6-CyclinD-Rb Pathway are Common in Human Cancer MFMER slide-15
16 Cyclin-dependent kinase Inhibitors 2016 MFMER slide-16
17 Palbociclib in ER+, HER- Breast Cancer PD LET (n = 84) LET (n = 81) Number of Events (%) 21 (25) 40 (49) Median PFS, months (95% CI) 26.1 ( ) 7.5 ( ) Hazard Ratio (95% CI) 0.37 ( ) p-value <0.001 Select Treatment-related adverse events Grade 3/4 AEs ( 10%) PD LET LET Neutropenia 61.4% 1.3% Leukopenia 16.9% 0% Anemia 6% 1.3% Fatigue 4.8% 1.3% Thrombocytopenia 1.2% 0% but beyond ER-positive status, CCND1 amplification or loss of the cyclin-dependent kinase inhibitor 2A (p16) did not seem to help to better select patients for treatment benefit. Finn RS et al. (2012) San Antonio Breast Cancer Symposium Abstract S MFMER slide-17
18 Abemaciclib in HR+ breast cancer Patnaik et al. Cancer Discovery MFMER slide-18
19 Ribociclib in HR+ breast cancer Hortobagyi et al. MONALEESA-2 ESMO 2016 Copenhagen 2016 MFMER slide-19
20 Future Outlook Inhibiting both CDK4 and CDK6 likely results in increased toxicity Cdk4 mice are viable - Cdk6 mice are viable Palbo/Ribo CDK4 CycD1 Abema CDK6 CycD3 Cdk4/6 double knockout mice die during embryonic development Eliminating CDK4 (or Cyclin D1) is sufficient to cure HER2+ breast tumors in mice Eliminating CDK6 (or Cyclin D3) is efficient in Notch+ leukemias in mice CDK4 specific inhibitors may be efficient against breast (epithelial?) cancers with reduced toxicity CDK6 specific inhibitors could be efficient against specific hematopoietic neoplasias with reduced toxicity? 2016 MFMER slide-20
21 Cancer occurs when something goes wrong with our genes DNA is the building block of a gene. Genes are stored in the chromosome A C T T G A G C 2016 MFMER slide-21
22 Gene Mutation 2016 MFMER slide-22
23 Chromosomal Aberrations 2016 MFMER slide-23
24 Genome Alterations Identified by NGS Meyerson et al, Nat Rev Gen MFMER slide-24
25 Driver Genes as Cancer Targets EGFR EML4-ALK Erlotinib, Gefitinib, Afatinib, Osimertinib Crizotinib, Alectinib, Ceritinib Bcr-abl HER2-neu B-raf Ret Hedgehog Ros-1 Imatinib, dasatinib,ponatinib Trastuzumab, perzutumab Vemurafenib, dabrafenib Vandetanib, cabozantinib Vismodegib Crizotinib 2016 MFMER slide-25
26 MET Inhibitors Peters and Adjei, Nat Rev Clin Oncol MFMER slide-26
27 MET and Exon 14 Splice Mutations 2016 MFMER slide-27
28 Slide MFMER slide-28
29 Lung Adenocarcinoma with MET Exon 14 splice mutations 2016 MFMER slide-29
30 Crizotinib for MET Exon 14 Mutations Slide MFMER slide-30
31 Slide MFMER slide-31
32 Genomics-based Therapy is Part of the future Future Directions 2016 MFMER slide-32
33 Current Hot Study Designs Baskets and Umbrellas 2016 MFMER slide-33
34 Umbrella Trial - Lung Master Protocol MFMER slide-34
35 Basket Trial NCI MATCH 2016 MFMER slide-35
36 2016 MFMER slide-36
37 2016 MFMER slide-37
38 Molecular Aberrations Being Targeted 2016 MFMER slide-38
39 Molecular Aberrations Being Targeted 2016 MFMER slide-39
40 Early Cancer Therapeutics Program at Mayo Clinic 2016 MFMER slide-40
41 Paramyxovirus The Measles Virus Negative stranded RNA virus nm Attenuated vaccine strain-edmonston strain 2016 MFMER slide-41
42 MV-NIS 2016 MFMER slide-42
43 Experiment of Nature Tumor Responses Following Incidental Viral Infection Mayo Clinic Proceedings DOI: ( /j.mayocp ) 2016 MFMER slide-43
44 Best Clinical Response 2016 MFMER slide-44
45 T-VEC: An HSV-1 Derived Oncolytic Immunotherapy Designed to Produce Both Local and Systemic Effects 2016 MFMER slide-45
46 T-VEC Responses in Injected and Uninjected Sites 2016 MFMER slide-46
47 Secondary Endpoint : Time to treatment Failure Durable Response rate 5.7% vs 26.4 % 2016 MFMER slide-47
48 Immune Modulation 2016 MFMER slide-48
49 Elements of an Anitbody Drug Complex (ADC) 2016 MFMER slide-49
50 The Mesothelin Protein 2016 MFMER slide-50
51 Mesothelin is highly expressed in many cancers 2016 MFMER slide-51
52 Mesothelin-Antibody Drug Conjugate : Anetumab Ravtansine 2016 MFMER slide-52
53 Clinical Activity of Anetumab Ravtansine 2016 MFMER slide-53
54 Mesothelin Expression in Cancer 2016 MFMER slide-54
55 Ravtansine in Advanced/Recurrent Malignancies 2016 MFMER slide-55
56 Two Types of Immune Responses Provide Extended Protection 1 Adaptive Immunity CANCEROUS CELLS Innate Immunity Physical Barriers The immune response can be divided into 2 types 1 Innate immune response Nonspecific and immediately available to fight a large range of pathogens Does not generate long-term protective immunity (immunologic memory) Adaptive immune response Specific response developed during lifetime as an adaptation to infection by pathogens Does generate immunologic memory, which confers life-long protection against reinfection with the same pathogen The innate and adaptive immune systems communicate with one another 1,2 1. Murphy K. Janeway s Immunobiology. 8th ed. New York, NY: Garland Science; Sompayrac L. How the Immune System Works. 4th ed. Oxford, UK: Wiley-Blackwell; MFMER slide-56
57 Mechanisms involved in adaptive T cell-mediated immunity against tumors and in its modulation exerted by CTLA-4 and PD-1/PD-L MFMER slide-57
58 The the anti-tumor immune response Chen and Mellman, Immunity. 25;39(1): MFMER slide-58
59 Immune Regulation via Costimulatory and Coinhibitory (Checkpoint) Receptors Multiple costimulatory and coinhibitory interactions regulate T- cell responses 1 Signaling via costimulatory molecules (eg, CD28, GITR) activates T cells 1,2 Signaling via coinhibitory (or checkpoint) molecules (eg, CTLA-4, PD-1, LAG-3) inhibits T-cell activation 1,2 Costimulatory Receptors Coinhibitory Receptors Image reprinted from Mellman I et al. Nature. 2011;480(7378): Pardoll DM. Nat Rev Cancer. 2012;12(4): Mellman I et al. Nature. 2011;480(7378): MFMER slide-59 41
60 Physiological Roles of Immune Checkpoint Pathways (cont) CTLA-4 pathway 1,2 Inhibits the activation of naïve and memory T cells at the lymph nodes, suppressing broad immune responses throughout the body CD80 CD28 DC MHC CD80 TCR CTLA-4 Naïve T cell - PD-1 pathway 1,2 Acts at sites of inflammation and tumor immunosuppression, inhibiting tumor-specific immune responses Tumor Cell PD-L1 PD-1 T cell - Images adapted from Pardoll DM. Nat Rev Cancer. 2012;12(4): Pardoll DM. Nat Rev Cancer. 2012;12(4): McDermott DF, Atkins MB. Cancer Medicine. 2013;2(5): MFMER slide-60 42
61 Physiological Roles of Immune Checkpoint Pathways (cont) TIM-3 immune checkpoint receptor Functions specifically to limit the duration and T m ce a ll gnitude of T-cell responses 1,2 DC GAL9 TIM3 T cell - LAG-3 immune checkpoint receptor Enhances the function of Tregs and can inhibit effector CD8+ T cells 2 DC MHC T cell TCR Signal 1 LAG3 - Image adapted from Pardoll DM. Nat Rev Cancer. 2012;12(4): GAL9 = galectin Anderson AC et al. Cancer Immunol Res. 2014;2(5): Pardoll DM. Nat Rev Cancer. 2012;12(4): MFMER slide-61 43
62 Physiological Roles of Costimulatory Pathways OX40-mediated costimulation 1,2 Promotes T-cell activation, survival, proliferation, and cytokine production DC OX40L OX40 T cell + GITR-mediated costimulation 2,3 Enhances proliferation and effector function of naïve T cells DC GITR-L GITR T cell + Image adapted from Pardoll DM. Nat Rev Cancer. 2012;12(4): Pardoll DM. Nat Rev Cancer. 2012;12(4): Schaer DA et al. J Immunother Cancer. 2014;2:7. 3. Bakdash G et al. Front Immunol. 2013;4: MFMER slide-62 44
63 Management of cancer in the post-anti-pd-1/l1 era Anti-PD-1/anti-PD-L1 Bring T cells into tumors: + anti-ctla4 + immune activating antibodies or cytokines + TLR agonists or oncolytic viruses + IDO or macrophage inhibitors + targeted therapies Generate T cells: Vaccines TCR engineered ACT CAR engineered ACT 2016 MFMER slide-63
64 Checkpoint Inhibitors are Expensive Pembrolizumab ($15,000/3 wks) Nivolumab ($14,000/4 wks) Ipilimumab q3wks x 4 doses ($120,000) Nivolumab + Ipilimumab = you do the math MFMER slide-64
65 HOW THE HECK DO THEY GET THOSE NAMES FOR ALL THESE ANTIBODIES? 2016 MFMER slide-65
66 Monoclonal Antibodies in Cancer Fab Fc Murine Ab momab Chimeric Mouse-Human Ab ximab Humanized Ab zumab Human Ab mumab 17-1A Cetuximab Bevacizumab Panitumumab 2016 MFMER slide-66
67 Nomenclature of Monoclonal Antibodies -mab monoclonal antibody -mo-mab mouse mab -xi-mab chimeric mab -zu-mab humanized mab -mu-mab human mab -tu-xx-mab tumor-directed xx mab -li-xx-mab immune-directed xx mab -ci-xx-mab cardiovascular-directed xx mab -vi-xx-mab virus-directed xx mab Ipilimumab; pembrolizumab; atezolizumab 2016 MFMER slide-67
68 MFMER slide-68
Immunotherapy and Targeted Therapies: The new face of cancer treatment
Immunotherapy and Targeted Therapies: The new face of cancer treatment Abdulazeez Salawu MBBS, MSc, PhD, MRCP Academic Clinical Lecturer Weston Park Hospital, Sheffield Novel Systemic Anti-cancer Therapies
More informationCancer immunity and immunotherapy. General principles
1 Cancer immunity and immunotherapy Abul K. Abbas UCSF General principles 2 The immune system recognizes and reacts against cancers The immune response against tumors is often dominated by regulation or
More informationTargeted Cancer Therapies
Targeted Cancer Therapies Primary Care Training Programme 14 th February 2018 Sin Chong Lau Consultant in Medical Oncology Financial Disclosure Honoraria: Amgen, Pfizer, Roche, Sanofi, Servier Meetings:
More informationImmuno-Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. February 24, 2016
Immuno-Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D February 24, 216 GSK Pipeline Oncology R&D strategy Focusing on 3 areas fundamental to oncology Cancer Epigenetics Long-Term Survival
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More information2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery
C007: Immunology of Melanoma: Mechanisms of Immune Therapies Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los Angeles Biomedical
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationImmune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich
Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3
More informationTumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School
Tumor Immunity and Immunotherapy Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School Lecture Outline Evidence for tumor immunity Types of tumor antigens Generation of anti-tumor
More informationNew Developments in the Treatment of Colorectal Cancer. Jonathan Loree, MD, MS, FRCPC Department of Medical Oncology BC Cancer Vancouver Centre
New Developments in the Treatment of Colorectal Cancer Jonathan Loree, MD, MS, FRCPC Department of Medical Oncology BC Cancer Vancouver Centre Personalized Medicine Currently already part of oncology:
More informationImmuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY
More information2/19/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery
F141: Advanced Melanoma: Mechanisms of Immune Therapies beyond Checkpoint blockade Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los
More informationPrecision Genetic Testing in Cancer Treatment and Prognosis
Precision Genetic Testing in Cancer Treatment and Prognosis Deborah Cragun, PhD, MS, CGC Genetic Counseling Graduate Program Director University of South Florida Case #1 Diana is a 47 year old cancer patient
More informationImmunotherapy Overview, Rationale, and Role in Clinical Practice
Immunotherapy Overview, Rationale, and Role in Clinical Practice Financial Disclosure Bradi L. Frei, PharmD, BCOP, BCPS has no relevant financial relationships with commercial interests to disclose. OBJECTIVES
More informationState of the Art in Development of Immunotherapy. Alex A. Adjei. ESMO AFRICA Cape Town February 15, MFMER slide-1
State of the Art in Development of Immunotherapy Alex A. Adjei ESMO AFRICA Cape Town February 15, 2018 2016 MFMER slide-1 DISCLOSURE OF INTEREST Alex A. Adjei Institutional financial interests : Clinical
More informationGSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017
GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics
More informationLung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17
Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD Mount Carrigain 2/4/17 Histology Adenocarcinoma: Mixed subtype, acinar, papillary, solid, micropapillary, lepidic
More informationIMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust
IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent
More informationTumor Immunology: A Primer
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationUnderstanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies. Michael A. Curran, Ph.D.
Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies Michael A. Curran, Ph.D. MD Anderson Cancer Center Department of Immunology Disclosures I have research
More informationBiologics Effects of Targeted Therapeutics
Report on the isbtc Mini-symposium on Biologics Effects of Targeted Therapeutics Michael B. Atkins, MD Beth Israel Deaconess Medical Center Louis Weiner, M.D. Fox Chase Cancer Center Report on the isbtc
More informationDeregulation of signal transduction and cell cycle in Cancer
Deregulation of signal transduction and cell cycle in Cancer Tuangporn Suthiphongchai, Ph.D. Department of Biochemistry Faculty of Science, Mahidol University Email: tuangporn.sut@mahidol.ac.th Room Pr324
More informationNew Oncology Drugs: Nadeem Ikhlaque, M.D Subtitle Would Go Here
New Oncology Drugs: A PowerPoint Brief Primer Cover Title Nadeem Ikhlaque, M.D 05.19.2017 Subtitle Would Go Here Learning Objectives List novel chemotherapies and the indications of these newer agents
More informationPersonalized Genetics
Personalized Genetics Understanding Your Genetic Test Results Tracey Evans, MD September 29, 2017 Genetics 101 Punnett Square Genetic Pedigree 2 Genetics 101 Punnett Square Genetic Pedigree 3 It s not
More informationCDK 4/6 Inhibitors: Efficacy and Side Effect Profile
CDK 4/6 Inhibitors: Efficacy and Side Effect Profile Univ.-Prof. Dr. Christian F Singer, MPH Center for Breast Health, Medical University of Vienna Center for Familial Breast- and Ovarian Cancer, MUW Christian
More informationNew Developments in Cancer Treatment. Dulcinea Quintana, MD
New Developments in Cancer Treatment Dulcinea Quintana, MD Mortality Rates Goals of treatment 1 Cure Goal of treatment 2 Prolong life Goals of treatment 3 Improve Quality of Life Goals of treatment 4
More information9/22/2016. Introduction / Goals. What is Cancer? Pharmacologic Strategies to Treat Cancer. Immune System Modulation
Immunomodulatory Therapies in Cancer Treatment Bill O Hara, PharmD, BCPS, BCOP Advanced Practice Pharmacist, Oncology/BMT Thomas Jefferson University Hospital Introduction / Goals What is Cancer? How can
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationCombining ADCs with Immuno-Oncology Agents
Combining ADCs with Immuno-Oncology Agents Chad May, PhD Senior Director Targeted Immunotherapy Oncology Research Unit, Pfizer 7 th Annual World ADC October 10, 2016 Cancer-Immunity Cycle Innate Immunity
More informationPersonalized Treatment Approaches for Lung Cancer
Personalized Treatment Approaches for Lung Cancer California Thoracic Society 2018 Annual Carmel Conference January 27, 2018 Matthew Gubens, MD, MS Associate Professor of Medicine Chair, Thoracic Oncology
More informationTargeting CDK 4/6. Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine
2016.04.30 GBCC Education Symposium Targeting CDK 4/6 Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine Contents Cyclins -CDKs in cell cycle control CDK 4/6 in breast cancer Preclinical
More informationLung Cancer Update 2016 BAONS Oncology Care Update
Lung Cancer Update 2016 BAONS Oncology Care Update Matthew Gubens, MD, MS Assistant Professor Chair, Thoracic Oncology Site Committee UCSF Helen Diller Family Comprehensive Cancer Center Disclosures Consulting
More informationScott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION
Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 11 T-Cell Activation, Differentiation, and Memory Copyright 2013 by W. H. Freeman and
More informationEmerging Targets in Immunotherapy
Emerging Targets in Immunotherapy So Jin Shin, M.D. Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu, Korea no-0ncology Todays is.. ancer Immunotherapy? nd immunotherapy
More informationImmune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic
Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers
More informationGiorgio V. Scagliotti Università di Torino Dipartimento di Oncologia
Giorgio V. Scagliotti Università di Torino Dipartimento di Oncologia giorgio.scagliotti@unito.it Politi K & Herbst R. Clin. Cancer Res. 2015; 21:2213 Breast Colorectal Gastric/GE Junction Tumor Type Head
More informationT Cell Activation, Costimulation and Regulation
1 T Cell Activation, Costimulation and Regulation Abul K. Abbas, MD University of California San Francisco 2 Lecture outline T cell antigen recognition and activation Costimulation, the B7:CD28 family
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationProfessor Mark Bower Chelsea and Westminster Hospital, London
Professor Mark Bower Chelsea and Westminster Hospital, London Cancer immunotherapy & HIV Disclosures: None Lessons for oncology from HIV Awareness and advocacy Activism Rational drug design Prescribing
More informationNSCLC 2 nd and further line therapies. Egbert F. Smit MD PhD. Dept. Thoracic Oncology, Netherlands Cancer Institute
NSCLC 2 nd and further line therapies Egbert F. Smit MD PhD. Dept. Thoracic Oncology, Netherlands Cancer Institute e.smit@nki.nl ESMO Guidelines 2016: Treatment of Stage IV nonsquamous NSCLC at progression
More informationNon-Small Cell Lung Cancer:
Non-Small Cell Lung Cancer: Where We Are Today Sila Shalhoub, PharmD PGY2 Oncology Pharmacy Resident Shalhoub.Sila@mayo.edu Pharmacy Grand Rounds September 26, 2017 2017 MFMER slide-1 Objectives Identify
More informationPersonalized Therapies for Lung Cancer. Questions & Answers
Personalized Therapies for Lung Cancer Questions & Answers What are Personalized Therapies for lung cancer? Like people, no two lung cancer tumors are the same. Personalized medicine (also known as precision
More informationDra. Omayra Reyes, MD. Hematologist- Oncologist. Introduction to Immuno Oncology
Dra. Omayra Reyes, MD. Hematologist- Oncologist Introduction to Immuno Oncology Disclosure I have no conflicts of interest Objectives Review Basic concepts of onco- immunology. Recognize different mechanisms
More information6/7/16. Melanoma. Updates on immune checkpoint therapies. Molecularly targeted therapies. FDA approval for talimogene laherparepvec (T- VEC)
Melanoma John A Thompson MD July 17, 2016 Featuring: Updates on immune checkpoint therapies Molecularly targeted therapies FDA approval for talimogene laherparepvec (T- VEC) 1 Mechanism of ac-on of Ipilimumab
More informationI. Diagnosis of the cancer type in CUP
Latest Research: USA I. Diagnosis of the cancer type in CUP II. Outcomes of site-specific therapy of the cancer type in CUP a. Prospective clinical trial b. Retrospective clinical trials 1 Latest Research:
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More informationAdvances in Systemic Therapy Hepatocellular Carcinoma (HCC) Dr ZEE Ying Kiat HASLD Conference Ho Chi Minh City, 18 December 2016
Advances in Systemic Therapy for Hepatocellular Carcinoma (HCC) Dr ZEE Ying Kiat HASLD Conference Ho Chi Minh City, 18 December 2016 Scope Background Staging and treatment strategies Current systemic therapy
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationOverview of Boehringer Ingelheim in Oncology
Overview of Boehringer Ingelheim in Oncology 2017 Conversations in Oncology in Shanghai, China Victoria Zazulina, MD BI Symposium Boehringer Ingelheim (BI) in Brief Family-owned global corporation Founded
More informationImmunotherapy of HNC: immune mechanisms and therapeutic targets
Immunotherapy of HNC: immune mechanisms and therapeutic targets Ourania Tsitsilonis, MD, PhD Department of Biology National & Kapodistrian University of Athens What does the Immune System see in Cancer?
More informationTargeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont. Masterclass 27 september 2018
Targeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont Masterclass 27 september 2018 Outline Introduction EGFR TKI ALK TKI TKI for uncommon driver mutations Take home messages The promise of
More informationTargeted Medicine and Molecular Therapeutics. Angus McIntyre, M.D. Medical Oncologist, Addison Gilbert Hospital and Beverly Hospital October 6, 2009
Targeted Medicine and Molecular Therapeutics Angus McIntyre, M.D. Medical Oncologist, Addison Gilbert Hospital and Beverly Hospital October 6, 2009 Approaches to Cancer Prevention Screening and early diagnosis
More informationCheckpoint Inhibition in Hodgkin s Lymphoma John Kuruvilla, MD & Rob Laister, PhD
Checkpoint Inhibition in Hodgkin s Lymphoma John Kuruvilla, MD & Rob Laister, PhD Disclosures for Rob Laister Research Support Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific
More informationNobel Prize in Physiology or Medicine 2018
Nobel Prize in Physiology or Medicine 2018 Arunika Mukhopadhaya The Nobel Prize in Physiology or Medicine for the year 2018 was awarded to James P Allison of the United States and Tasuku Honjo of Japan
More informationMultimedia Appendix 6 Educational Materials Table of Contents. Intervention Educational Materials Audio Script (version 1)
Multimedia Appendix 6 Educational Materials Table of Contents Intervention Educational Materials... 1 Audio Script (version 1)... 1 Text (version 1)... 5 Slides (version 1)... 17 Audio Script (version
More informationTumor Microenvironment and Immune Suppression
Tumor Microenvironment and Immune Suppression Hassane M. Zarour,, MD Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh Cancer Institute Hallmarks of Cancer: The Next Generation
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationTargeted Therapy Vijay Narang
25 Volume 1, Issue 1, January 2013, Online: Targeted Therapy Vijay Narang ABSTRACT This is a review on targeted therapy that blocks the growth and spread of cancer by interfering with specific molecules
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationImmune Tolerance. Kyeong Cheon Jung. Department of Pathology Seoul National University College of Medicine
Immune Tolerance Kyeong Cheon Jung Department of Pathology Seoul National University College of Medicine Immune tolerance Unresponsiveness to an antigen that is induced by previous exposure to that antigen
More informationBasic Principles of Tumor Immunotherapy. Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA
Basic Principles of Tumor Immunotherapy Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA Disclosures Consulting Fees: Biodesix, Novartis Pharmaceuticals Other: Boehringer
More information6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
More informationUpdate on Melanoma Treatment. Tara C Mitchell, MD
Update on Melanoma Treatment Tara C Mitchell, MD Overview Immune therapy update Targeted therapy update New concepts in treating melanoma What is the immune system? A complex network of protective cells
More informationTHE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network THE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum
More informationPriming the Immune System to Kill Cancer and Reverse Tolerance. Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics
Priming the Immune System to Kill Cancer and Reverse Tolerance Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics Learning Objectives Describe the role of the immune system in cancer
More informationNCCN Non Small Cell Lung Cancer V Meeting July 8, 2016
NSCL 3 Submission from Myriad requesting the following statement to be listed as an additional high risk factor in footnote p : For lung ADC, a highrisk 46 gene molecular prognostic score determined by
More informationNew Developments in Cancer Treatment. Ian Rabinowitz MD
New Developments in Cancer Treatment Ian Rabinowitz MD Treatment Outline Angiogenesis inhibition Targeted therapy Immunotherapy Personalization of therapy Genomics and cancer Stem cells and cancer Angiogenesis
More informationTargeting Oncogenic Drivers
Targeting Oncogenic Drivers Yujie Zhao Alex A. Adjei Department of Medicine, Roswell Park Cancer Institute, Buffalo, N.Y., USA Abstract Cancer is a genetic disease caused by a series of somatic and/or
More informationDrug-targeted therapies and Predictive Prognosis: Changing Role for the Pathologist
Drug-targeted therapies and Predictive Prognosis: Changing Role for the Pathologist Moderator: S. Terence Dunn, Ph.D. Associate Professor, Pathology Director, Molecular Pathology Laboratory University
More informationOTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento
OTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento Dolores Isla Servicio de Oncología Médica HCU Lozano Besa de Zaragoza 2008 Selection Factors in Advanced NSCLC ( 8y ago)
More informationTargeted therapies for advanced non-small cell lung cancer. Tom Stinchcombe Duke Cancer Insitute
Targeted therapies for advanced non-small cell lung cancer Tom Stinchcombe Duke Cancer Insitute Topics ALK rearranged NSCLC ROS1 rearranged NSCLC EGFR mutation: exon 19/exon 21 L858R and uncommon mutations
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationCancer immunotherapy with oncolytic viruses: more than just lysis
Cancer immunotherapy with oncolytic viruses: more than just lysis Dmitriy Zamarin MD PhD Assistant Attending, Immune Therapeutics Center Memorial Sloan-Kettering Cancer Center New York, NY BCAN Think Tank
More informationRAS Genes. The ras superfamily of genes encodes small GTP binding proteins that are responsible for the regulation of many cellular processes.
۱ RAS Genes The ras superfamily of genes encodes small GTP binding proteins that are responsible for the regulation of many cellular processes. Oncogenic ras genes in human cells include H ras, N ras,
More informationEmerging Tissue and Serum Markers
Emerging Tissue and Serum Markers for Immune Checkpoint Inhibitors Kyong Hwa Park MD, PhD Medical Oncology Korea University College of Medicine Contents Immune checkpoint inhibitors in clinical practice
More informationImmunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells
Immunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells Andrew H. Lichtman, M.D. Ph.D. Department of Pathology Brigham and Women s Hospital and Harvard
More informationRole of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney
Role of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney Consultant Thoracic Pathologist Royal Liverpool University Hospital Disclosure JRG is a paid advisor
More informationThe Role of Immunotherapy in Prostate Cancer: What s Trending?
The Role of Immunotherapy in Prostate Cancer: What s Trending? Douglas G. McNeel, MD, PhD University of Wisconsin Carbone Cancer Center Madison, Wisconsin Prostate cancer rationale for immune therapies
More informationRIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO. Dra. Elena Aguirre H.U. Miguel Servet
RIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO Dra. Elena Aguirre H.U. Miguel Servet INTRODUCTION ADVANCED BREAST CANCER HR+/HER2- YES Consider Chemo VISCERAL CRISIS? NO Endocrine Therapy X3 Toxicity Progresive
More information1.Basis of resistance 2.Mechanisms of resistance 3.How to overcome resistance. 13/10/2017 Sara Redaelli
Dott.ssa Sara Redaelli 13/10/2017 1.Basis of resistance 2.Mechanisms of resistance 3.How to overcome resistance Tumor Heterogeneity: Oncogenic Drivers in NSCLC The Promise of Genotype-Directed Therapy
More informationImmunotherapy on the Horizon: Adoptive Cell Therapy
Immunotherapy on the Horizon: Adoptive Cell Therapy Joseph I. Clark, MD, FACP Professor of Medicine Loyola University Chicago Stritch School of Medicine Maywood, IL June 23, 2016 Conflicts of Interest
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationCancer Progress. The State of Play in Immuno-Oncology
Cancer Progress The State of Play in Immuno-Oncology Axel Hoos, MD, PhD VP, Oncology R&D, Glaxo Smith Kline Co-Director, Cancer Immunotherapy Consortium Key Drivers in Immuno-Oncology Science Methods Combinations
More informationBasic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression. Bryon Johnson, PhD
Basic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression Bryon Johnson, PhD Disclosures There will be discussion about the use of products for non-fda indications in this presentation.
More informationD Ross Camidge, MD, PhD
i n t e r v i e w D Ross Camidge, MD, PhD Dr Camidge is Director of the Thoracic Oncology Clinical Program and Associate Director for Clinical Research at the University of Colorado Cancer Center in Aurora,
More informationTreating cancer in HIV infected patients. Professor Mark Bower National Centre for HIV malignancy Chelsea & Westminster Hospital
Treating cancer in HIV infected patients Professor Mark Bower National Centre for HIV malignancy Chelsea & Westminster Hospital AIDS defining malignancies Malignancy Kaposi s sarcoma Virus KSHV Rate ratio
More informationASCO Annual Meeting 2017 Bart Neyns MD PhD, UZ Brussel. 20th Post-ASCO Meeting, 24th June 2016
IMMUNOTHERAPY @the ASCO Annual Meeting 2017 Bart Neyns MD PhD, UZ Brussel 20th Post-ASCO Meeting, 24th June 2016 FAS-L Cancer Testis Ag Differentiation Ag Neo-antigens PD-1 CTL CD8+ Tcell CTLA-4 CD28 B7.1/B7.2
More informationImmunotherapy for the Treatment of Brain Metastases
Society for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases Lawrence G. Lum, MD, DSc Karmanos Cancer Institute and Wayne State University Advances in Cancer Immunotherapy
More informationDisclosure Information. Mary L. Disis
Disclosure Information Mary L. Disis I have the following financial relationships to disclose: Consultant for: VentiRx, Celgene, Emergent, EMD Serono Speaker s Bureau for: N/A Grant/Research support from:
More informationIntroduction. Cancer Biology. Tumor-suppressor genes. Proto-oncogenes. DNA stability genes. Mechanisms of carcinogenesis.
Cancer Biology Chapter 18 Eric J. Hall., Amato Giaccia, Radiobiology for the Radiologist Introduction Tissue homeostasis depends on the regulated cell division and self-elimination (programmed cell death)
More informationImpact of Targeted/Immunotherapy on Gamma Knife Radiosurgery
Impact of Targeted/Immunotherapy on Gamma Knife Radiosurgery Veronica Chiang, MD Yale University Department of Neurosurgery IGKRF Scientific Session University of Pennsylvania, Philadelphia June 23-24,
More informationNCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018
Guideline Page and Request Illumina Inc. requesting to replace Testing should be conducted as part of broad molecular profiling with Consider NGS-based assays that include EGFR, ALK, ROS1, and BRAF as
More informationProf. R. V. Skibbens
Prof. R. V. Skibbens December 2, 2011 BIOS 10: BioScience in the 21 st Century Cell Cycle, Cell Division and Cancer (Part 2) Directionality The Cell Cycle clock goes in only one direction S-phase cells
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Cervix
More informationIntegration of Genomics Into Clinical Pathways. Precision Medicine and Decision Support
Integration of Genomics Into Clinical Pathways Precision Medicine and Decision Support Faculty Andrew Hertler, MD, FACP Chief Medical Officer New Century Health Andrew Hertler, MD, FACP is employed by
More informationT-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:
Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,
More informationT-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:
Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,
More informationExploring Immunotherapies: Beyond Checkpoint Inhibitors
Exploring Immunotherapies: Beyond Checkpoint Inhibitors Authored by: Jennifer Dolan Fox, PhD VirtualScopics (Now part of BioTelemetry Research) jennifer_fox@virtualscopics.com +1 585 249 6231 Introduction
More informationMelanoma 10/12/18 Justin J. Baker, M.D.
Objectives Review Incidence Risk Factors for Development Detection 10/12/18 Justin J. Baker, M.D. Treatment of Surgery Medicine Radiation What is Incidence Cancer of Melanocytes Melanocytes are normal
More information